Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Illumina, Inc.NASDAQ: ILMN
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $40M (cash outflow) rose 73.9% year over year, ahead of the +26.8% change in trailing-twelve-month capital expenditures. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.
Context
- Capital expenditures amounted to 3.4% of revenue in FY2025, up 0.5 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +73.9% holds above the trailing-twelve-month pace of +26.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (148M) USD
- Year-over-year change
- -15.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | (148M) | -15.6% |
| FY2024 | 2024-12-29 | (128M) | +34.4% |
| FY2023 | 2023-12-31 | (195M) | +31.8% |
| FY2022 | 2023-01-01 | (286M) | -37.5% |
| FY2021 | 2022-01-02 | (208M) | — |
Capital Expenditures vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 capital expenditures of $156M is the 2nd largest of the 11 companies compared; the peer median is $17.69M.
- Its year-over-year change of +26.8% is the 5th highest of 10, against a peer median of -11.5%.
- Capital expenditures amounts to 3.5% of revenue for ILMN, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $156.54M | +90.6% | +30.6% | 5.8% | |
| LTM Jun 2026 | $156M | +26.8% | -19.7% | 3.5% | |
| LTM Sep 2026 | $58.67M | +49.2% | -14.6% | 4.6% | |
| LTM Jun 2026 | $29.4M | -11.5% | -4.4% | 3.8% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $27.09M | +122.1% | +9.9% | 6.0% |
| LTM Mar 2026 | $23.2M | -21.1% | -29.9% | 2.8% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.18M | — | — | 3.1% |
| LTM Jun 2026 | $5.65M | -43.9% | -64.4% | 0.9% | |
| LTM Mar 2026 | $5.19M | +29.3% | -55.1% | 8.0% | |
| LTM Mar 2026 | $4.37M | -49.8% | -45.7% | 2.7% | |
| LTM Mar 2026 | $3.31M | -57.1% | -61.9% | 4.1% | |
| Peer median (excluding ILMN) | $17.69M | -11.5% | -29.9% | 4.0% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| Deferred Income Tax | (76M) | (23M) | (33M) | (112M) | 119M |
| Stock-Based Compensation | 754M | 366M | 380M | 370M | 275M |
| Change in Working Capital | (152M) | 204M | (90M) | (483M) | (153M) |
| Accounts Receivables | (164M) | (12M) | (40M) | (25M) | (108M) |
| Inventory | (58M) | (135M) | (20M) | 19M | (17M) |
| Accounts Payables | 60M | (38M) | (44M) | (4M) | 2M |
| Other Working Capital | 10M | 389M | 14M | (473M) | (30M) |
| Other Non-Cash Items | (994M) | 3.86B | 950M | 1.93B | (282M) |
| Operating Cash Flow | 545M | 392M | 478M | 837M | 1.08B |
| Capital Expenditures | (208M) | (286M) | (195M) | (128M) | (148M) |
| Acquisitions (Net) | (2.44B) | (265M) | (29M) | 2M | (10M) |
| Purchases of Investments | (77M) | (40M) | (6M) | (52M) | 0 |
| Sales of Investments | 1.66B | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | 103M |
| Investing Cash Flow | (1.07B) | (591M) | (231M) | (178M) | (55M) |
| Debt Repayment | 471M | 991M | (1.24B) | 491M | (5M) |
| Common Stock Issued | 60M | 63M | 67M | 56M | 44M |
| Common Stock Repurchased | 0 | 0 | 0 | (116M) | (742M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (582M) | (54M) | (42M) | (1B) | (41M) |
| Financing Cash Flow | (51M) | 1B | (1.21B) | (570M) | (744M) |
| Effect of Forex Changes | (3M) | (22M) | 0 | (10M) | 11M |
| Net Change in Cash | (578M) | 779M | (963M) | 79M | 291M |
| Free Cash Flow | 337M | 106M | 282M | 709M | 931M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.